20/20 BioLabs commenced trading on the Nasdaq Capital Market under the ticker AIDX following three consecutive years of sales growth. The company entered a contingent financing agreement for up to $40 million, with the first $5 million expected to close on listing day, contingent on meeting performance metrics.

The OneTest™ for Cancer blood test leverages AI models trained on real-world data to analyze tumor-associated protein biomarkers. Its design allows for home collection via an upper-arm device, offering a lower price point than competing ctDNA-based multi-cancer early detection tests while targeting lung, pancreatic, ovarian, liver and other cancers at treatable stages.

A new OneTest™ for Longevity, tracking inflammatory biomarkers linked to heart disease, dementia, diabetes and other chronic conditions, is slated to launch by the end of February. The test aims to help consumers monitor inflammation-related disease risk and make lifestyle adjustments to slow aging.

Recent legislation paves the way for Medicare coverage of multi-cancer early detection tests by 2028, potentially opening a substantial revenue stream. The company plans to pursue organic growth and strategic roll-ups of diagnostics firms, positioning itself for profitability and aligning with federal healthcare initiatives supporting preventive screenings.